Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × sapanisertib × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma 1 Neurofibrosarcoma 1 Leiomyosarcoma 1 Histiocytoma, Malignant Fibrous 1 Gliosarcoma 1 Glioblastoma 1 Dermatofibrosarcoma 1

Interventions

Doxorubicin 142 Ifosfamide 85 Radiotherapy 82 Cyclophosphamide 72 Gemcitabine 63 Filgrastim 54 pembrolizumab 43 pazopanib 40 Etoposide 39 Docetaxel 39 Vincristine 37 Trabectedin 37 Cisplatin 35 Nivolumab 32 Magnetic Resonance Spectroscopy 26 Irinotecan 26 Carboplatin 25 Temozolomide 23 Surgical Procedures, Operative 23 Radiation 22 Ipilimumab 22 Blood Specimen Collection 19 Bevacizumab 19 Biopsy 18 eribulin 17 Sirolimus 17 Mesna 17 Melphalan 17 Granulocyte Colony-Stimulating Factor 17 Dactinomycin 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Fox Chase Cancer Center

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡